Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Merck, Eisai Announced That Phase 3 LEAP-001 Trial Of Keytruda Plus Lenvima Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-Free Survival For The First-line Treatment For Patients With Advanced Or Recurrent Endometrial Cancer

Author: Benzinga Newsdesk | December 08, 2023 07:48am

Posted In: ESALF MRK